Literature DB >> 26637668

Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.

Anna A Marusiak1, Natalie L Stephenson1, Hayeon Baik1, Eleanor W Trotter1, Yaoyong Li2, Karen Blyth3, Susan Mason3, Phil Chapman2, Lorena A Puto4, Jon A Read5, Claire Brassington6, Hannah K Pollard6, Chris Phillips5, Isabelle Green6, Ross Overman6, Matthew Collier6, Ewelina Testoni1, Crispin J Miller7, Tony Hunter4, Owen J Sansom3, John Brognard8.   

Abstract

MLK4 is a member of the mixed-lineage family of kinases that regulate the JNK, p38, and ERK kinase signaling pathways. MLK4 mutations have been identified in various human cancers, including frequently in colorectal cancer, where their function and pathobiological importance have been uncertain. In this study, we assessed the functional consequences of MLK4 mutations in colon tumorigenesis. Biochemical data indicated that a majority of MLK4 mutations are loss-of-function (LOF) mutations that can exert dominant-negative effects. In seeking to understand the abrogated activity of these mutants, we elucidated a new MLK4 catalytic domain structure. To determine whether MLK4 is required to maintain tumorigenic phenotypes, we reconstituted its signaling axis in colon cancer cells harboring MLK4-inactivating mutations. We found that restoring MLK4 activity reduced cell viability, proliferation, and colony formation in vitro and delayed tumor growth in vivo. Mechanistic investigations established that restoring the function of MLK4 selectively induced the JNK pathway and its downstream targets, cJUN, ATF3, and the cyclin-dependent kinase inhibitors CDKN1A and CDKN2B. Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26637668      PMCID: PMC4740929          DOI: 10.1158/0008-5472.CAN-15-0701-T

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  Mutational analysis of the tyrosine kinome in colorectal cancers.

Authors:  Alberto Bardelli; D Williams Parsons; Natalie Silliman; Janine Ptak; Steve Szabo; Saurabh Saha; Sanford Markowitz; James K V Willson; Giovanni Parmigiani; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2003-05-09       Impact factor: 47.728

2.  Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation.

Authors:  A Behrens; W Jochum; M Sibilia; E F Wagner
Journal:  Oncogene       Date:  2000-05-18       Impact factor: 9.867

3.  Suppression of Ras-stimulated transformation by the JNK signal transduction pathway.

Authors:  Norman J Kennedy; Hayla K Sluss; Stephen N Jones; Dafna Bar-Sagi; Richard A Flavell; Roger J Davis
Journal:  Genes Dev       Date:  2003-03-01       Impact factor: 11.361

4.  The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression.

Authors:  Daniel Schramek; Athanassios Kotsinas; Arabella Meixner; Teiji Wada; Ulrich Elling; J Andrew Pospisilik; G Gregory Neely; Ralf-Harun Zwick; Verena Sigl; Guido Forni; Manuel Serrano; Vassilis G Gorgoulis; Josef M Penninger
Journal:  Nat Genet       Date:  2011-02-13       Impact factor: 38.330

5.  JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate.

Authors:  Anette Hübner; David J Mulholland; Claire L Standen; Maria Karasarides; Julie Cavanagh-Kyros; Tamera Barrett; Hongbo Chi; Dale L Greiner; Cathy Tournier; Charles L Sawyers; Richard A Flavell; Hong Wu; Roger J Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

6.  Dimerization via tandem leucine zippers is essential for the activation of the mitogen-activated protein kinase kinase kinase, MLK-3.

Authors:  I W Leung; N Lassam
Journal:  J Biol Chem       Date:  1998-12-04       Impact factor: 5.157

7.  Role of JNK in a Trp53-dependent mouse model of breast cancer.

Authors:  Cristina Cellurale; Claire R Weston; Judith Reilly; David S Garlick; D Joseph Jerry; Hayla K Sluss; Roger J Davis
Journal:  PLoS One       Date:  2010-08-30       Impact factor: 3.240

Review 8.  Role of mitogen-activated protein kinase kinase 4 in cancer.

Authors:  A J Whitmarsh; R J Davis
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

9.  Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis.

Authors:  Miriam Martini; Mariangela Russo; Simona Lamba; Elisa Vitiello; Emily Hannah Crowley; Francesco Sassi; Davide Romanelli; Milo Frattini; Antonio Marchetti; Alberto Bardelli
Journal:  Cancer Res       Date:  2013-01-14       Impact factor: 12.701

10.  BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?

Authors:  Sérgia Velho; Cátia Moutinho; Luís Cirnes; Cristina Albuquerque; Richard Hamelin; Fernando Schmitt; Fátima Carneiro; Carla Oliveira; Raquel Seruca
Journal:  BMC Cancer       Date:  2008-09-09       Impact factor: 4.430

View more
  10 in total

1.  Osmotic and heat stress-dependent regulation of MLK4β and MLK3 by the CHIP E3 ligase in ovarian cancer cells.

Authors:  Natalya A Blessing; Srimathi Kasturirangan; Evan M Zink; April L Schroyer; Deborah N Chadee
Journal:  Cell Signal       Date:  2017-07-28       Impact factor: 4.315

2.  Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors.

Authors:  Antonio Pannuti; Aleksandra Filipovic; Chindo Hicks; Elliot Lefkowitz; Travis Ptacek; Justin Stebbing; Lucio Miele
Journal:  PLoS One       Date:  2018-03-23       Impact factor: 3.240

3.  Mixed lineage kinase-4 promotes gastric carcinoma tumorigenesis through suppression of the c-Jun N-terminal kinase signaling pathway.

Authors:  Yu Xi; Jianhua Niu; Dongmei Li; Jiagen He; Le Qin; Xinyu Peng
Journal:  Exp Ther Med       Date:  2018-08-20       Impact factor: 2.447

Review 4.  Orange is the new black: Kinases are the new master regulators of tumor suppression.

Authors:  Elvira An; John Brognard
Journal:  IUBMB Life       Date:  2018-12-11       Impact factor: 3.885

5.  Pan-cancer whole-genome analyses of metastatic solid tumours.

Authors:  Peter Priestley; Jonathan Baber; Martijn P Lolkema; Neeltje Steeghs; Ewart de Bruijn; Charles Shale; Korneel Duyvesteyn; Susan Haidari; Arne van Hoeck; Wendy Onstenk; Paul Roepman; Mircea Voda; Haiko J Bloemendal; Vivianne C G Tjan-Heijnen; Carla M L van Herpen; Mariette Labots; Petronella O Witteveen; Egbert F Smit; Stefan Sleijfer; Emile E Voest; Edwin Cuppen
Journal:  Nature       Date:  2019-10-23       Impact factor: 49.962

6.  MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance.

Authors:  Dawid Mehlich; Michał Łomiak; Aleksandra Sobiborowicz; Alicja Mazan; Dagmara Dymerska; Łukasz M Szewczyk; Anna Mehlich; Agnieszka Borowiec; Monika K Prełowska; Adam Gorczyński; Paweł Jabłoński; Ewa Iżycka-Świeszewska; Dominika Nowis; Anna A Marusiak
Journal:  Cell Death Dis       Date:  2021-11-27       Impact factor: 8.469

7.  Chemical Composition and the Anticancer, Antimicrobial, and Antioxidant Properties of Acacia Honey from the Hail Region: The in vitro and in silico Investigation.

Authors:  Walid Sabri Hamadou; Nouha Bouali; Riadh Badraoui; Ramzi Hadj Lajimi; Assia Hamdi; Mousa Alreshidi; Mitesh Patel; Mohd Adnan; Arif Jamal Siddiqui; Emira Noumi; Visweswara Rao Pasupuleti; Mejdi Snoussi
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-04       Impact factor: 2.650

8.  Chemical IN04 Inhibits the Kinase Domain not the ROC Domain of LRRK1: Results from Homology Modeling and Molecular Docking.

Authors:  Zhenhang Chen; Weirong Xing; Li Fan
Journal:  Med Chem       Date:  2021       Impact factor: 2.745

9.  Extracellular translationally controlled tumor protein promotes colorectal cancer invasion and metastasis through Cdc42/JNK/ MMP9 signaling.

Authors:  Bin Xiao; Daxiang Chen; Shuhong Luo; Wenbo Hao; Fangyan Jing; Tiancai Liu; Suihai Wang; Yan Geng; Linhai Li; Weiwen Xu; Yajie Zhang; Xiaoqing Liao; Daming Zuo; Yingsong Wu; Ming Li; Qiang Ma
Journal:  Oncotarget       Date:  2016-08-02

10.  Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types.

Authors:  Nadia Terranova; Mendel Jansen; Martin Falk; Bart S Hendriks
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-04       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.